Sound stress exposure prolonged the period of decreased withdrawal threshold after complete Freund’s adjuvant (CFA) injection. by Satoka Kasai (3861115)

“…They showed a significant decrease in 50% withdrawal threshold on day 7 after CFA injection, and CFA-treated mice exposed to sound stress showed a significant decrease in 50% withdrawal threshold during days 7–21 after CFA injection (CFA, on day 7, ****<i>P</i> < 0.001 vs day 0, on day 10, ***<i>P</i> < 0.001 vs day0; CFA + stress, day 7, 10, 14, and 21, ****<i>P</i> < 0.0001 vs day 0, Dunnett’s test). …”

Decreased synthesis of VCAM-1, tubulin and dynein proteins in the heart of mice stimulated with EVs (green) or ICs (blue). by Alberto Cornet-Gomez (10676133)

“…<p>Confocal microscopy images of heart sections incubated with specific antibodies against VCAM-1 <b>(A)</b>, tubulin <b>(B)</b> and dynein <b>(C)</b> showed a decrease in fluorescence signals in samples from the EVs and ICs groups. …”

The flexural lumber properties of Pinus patula Schiede ex Schltdl. & Cham. improve with decreasing initial tree spacing by Justin Erasmus (8702619)

“…After accounting for ring width differences, there remained a significant effect of initial spacing on the parameters of models predicting microfibril angle and wood density.…”

FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection. by Penghui Hu (695020)

Cells lacking Cbf11 and/or Mga2 display nutrient-responsive decrease in lipid droplet (LD) content. by Anna Marešová (14375187)

Newly occurring LTSA-MD cases in workers for over a month. by Yasuhiko Deguchi (3167955)

The Ishihara test for colourblindness [41] encompasses stimuli that can determine the degree and type of colourblindness a person has. by Marcel F. Hinss (14675457)

Model A: Logistic structural model. by Abigail A. Lee (19935335)

“…Additionally, higher income slightly predicted decreased HPV vaccine hesitancy. All other latent variables and covariates were not significantly predictive of intent to vaccinate in the overall structural mode. …”

Starvation improves locomotory capacity and decreases the number of α-synuclein-YFP aggregates of transgenic <i>C. elegans</i> through LMP-1 dependent mechanism. by María Gallardo-Campos (22170919)

Results of two-way ANCOVA for <i>InR</i> and <i>Thor</i> expression differences by temperature and nutritional state interaction with <i>FoxO</i> as a covariate. by Tucker Hopkins (20790529)

Table 1_Dual variants of uncertain significance in a case of hyper-IgM syndrome: implications for diagnosis and management.docx by Nourhen Agrebi (14151222)

“…</p>Methods<p>We present immunological and genetic analysis of a Tunisian patient with two homozygous variants of uncertain significance (VUSs) in the IKBKB and AICDA genes, suspected of causing hyper-IgM and immune deficiency. …”

(A and B) ChIP-qPCR analysis of HSF2 binding to the indicated KSHV genomic regions expressed as % of input in KSHV infected latent (A) and lytic (B) cells. by Lorenza Cutrone (21144285)

Summary map of all contacts with statistically significant SVM classifications. by Alexander P. Rockhill (6053618)

“…Yellow indicates an increase in time-frequency clusters during number trials versus inter-trial intervals while blue indicates a decrease in time-frequency clusters. White regions in the plot indicate that no directional change occurred. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Distribution of KTAS levels and outcomes in the study population by age. by Hun Gi Lee (21526538)

Subjects:

Demographic characteristics of the study population. by Hun Gi Lee (21526538)

Subjects: